Shares of Arch Therapeutics Inc (NASDAQ:ARTH) have been given an average rating of “Hold” by the six ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $2.83.
A number of research analysts have recently weighed in on the stock. ValuEngine raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. Roth Capital set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 25th. Zacks Investment Research cut shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Finally, HC Wainwright set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th.
WARNING: “Arch Therapeutics Inc (NASDAQ:ARTH) Receives Consensus Recommendation of “Hold” from Brokerages” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/08/18/brokerages-set-arch-therapeutics-inc-nasdaqarth-pt-at-2-83-updated-updated.html.
Arch Therapeutics (NASDAQ ARTH) traded down 0.36% during midday trading on Friday, reaching $0.69. The company’s stock had a trading volume of 106,407 shares. The company’s market cap is $101.44 million. Arch Therapeutics has a 12-month low of $0.41 and a 12-month high of $0.80. The firm has a 50 day moving average price of $0.63 and a 200-day moving average price of $0.59.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
